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Abstract Fabry disease is an X-linked lysosomal storage dis-
order caused by the impairment ofα-galactosidase A. Enzyme
replacement therapy is available to treat patients, who often
experience delayed diagnosis. A newborn screening for Fabry
disease was performed to study the prevalence of the pathol-
ogy and to evaluate the possibility to implement the test in
systematic screenings. We collected 14,600 dried blood spot
samples (7575 males and 7025 females) and carried out a
diagnostic study by fluorometric measurement of α-
galactosidase A enzymatic activity andGLA gene sequencing.
We detected one patient with a mutation in GLA associated
with classical Fabry Disease (M290I), ten subjects carrying
genetic variants of uncertain diagnosis (S126G, R118C,
A143T), and a girl with the non-characterized variant F18Y,
which was not previously described. Additional 25 samples
presented nucleotide substitutions described as polymor-
phisms (D313Y, rs2071225, and rs2071397). The estimated
prevalence for Fabry disease in north-western Spanish males
is of 0.013%.
Conclusion: These results confirm that the prevalence of
Fabry disease is underestimated and systematic screening is
feasible; however, further characterization of variants of un-
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certain clinical significance is necessary to establish protocols
of patients’ management.
What is Known:
• Fabry disease is a rare disease of delayed diagnosis, whose prevalence
is underestimated. However, early diagnosis is important for better
efficiency of the current available treatment.
What is New:
• This newborn screening for Fabry disease performed on Spanish
population reveals a prevalence of genetic alterations in GLA of 0.1%
in males (0.013% with classic Fabry disease) and also characterizes
these modifications in order to discriminate between pathogenic
mutations and genetic variants of unknown significance.
Keywords Fabry disease . Newborn screening . Lysosomal
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Abbreviations
ACHDNC Advisory Committee on Hereditable Disorders
in Newborns and Children
CF Cystic fibrosis
DBS Dried blood spots
FD Fabry disease
GVUS Genetic variants of unknown significance
LSDs Lysosomal storage disorders
MPS Mucopolysaccharidosis
NBS Newborn screening
PPV Positive predictive value
SNP Single nucleotide polymorphism
α-GalA α-Galactosidase A
Introduction
Lysosomal storage disorders (LSDs) are good candidates for
newborn screening (NBS) since there are diagnostic methods
and treatments available [1, 2]. Indeed, Pompe disease and
mucopolysaccharidosis I (MPS I) were included by the
Advisory Committee on Hereditable Disorders in Newborns
and Children (ACHDNC) in the recommended uniform
screening panels (RUSP). This board, which was created by
the US Department of Health and Human Services to harmo-
nize NBS panels and methodologies, also evaluated the suit-
ability of early detection for other LSDs, such as Krabbe dis-
ease or Fabry disease (FD, OMIM#301500) [3, 4].
In FD, NBS has questionable benefits since the onset of
the pathology occurs in adult age and available treatments
present important limitations (i.e., low half-life, bioavail-
ability, and compliance, as well as possible immunogenic-
ity). Furthermore, the benefits of treating it since early
childhood are still uncertain [5, 6].
An additional point of discussion is the frequent detec-
tion of variants in the GLA gene (NC_000023.1, mRNA
NM_000169.2) with unclear diagnostic interpretation (i.e.,
p.A143T, p.R118C, p.E66Q…), which complicates the
management of subjects identified in FD screenings.
These variants have been related to a late-onset phenotype,
and patients are occasionally treated with enzyme replace-
ment therapy [7, 8].
Due to these controversial issues, ACHDNC rejected to
include FD in RUSP in their first evaluation; however, local
laws supported by newborn screening advocates and parents
allowed the implementation of systematic screening for FD in
Illinois and Missouri, which was also facilitated by the devel-
opment of cost-sustainable protocols. Pilot studies have also
been performed in other states, such as New Jersey and New
Mexico, among others [9]. Currently, the discussion on in-
cluding FD in the RUSP is re-opened due to the development
of more compliant treatments, based on orally administering
pharmaceutical chaperones. Migalastat (Galafold® Amicus
therapeutics) is up to date the only pharmacological chaperon
for FD, which obtained the European Medicine Agency
(EMA) approval for commercialization [10].
The aim of this study is to estimate the prevalence of FD in
the population of Galicia (north-west of Spain) and to evaluate
whether it is feasible to include this disease in the NBS pro-
gram implemented by the public healthcare system of our
region, which is currently detecting over 20 metabolic
diseases.
Materials and methods
Aim and design of the studyA newborn screening for Fabry
disease was performed to study the real prevalence of the
pathology in our region and to evaluate the possibility to im-
plement the test in systematic screenings. We carried out a
diagnostic study based on enzymatic screening of α-
galactosidase A.
Subjects The enzymatic screening was performed in asymp-
tomatic newborns by collecting dried blood spots (DBSs)
from 14,600 individuals (7575 males and 7025 females)
who represent 99% of all births in Galicia during the year
2008. Although enzymatic tests are not reliable in screening
females, we decided to perform the analysis also in females to
estimate if prevalence in males was significantly different
from the prevalence in the whole population. This would pro-
vide an indirect measure of the number of females that the
enzymatic test fails to detect.
Protocol Samples were gathered between day 3 and 5 after
birth. Clinical history of the subjects was consulted by autho-
rized physicians through the Galician Healthcare System
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Clinical History Database (IANUS) in order to collect symp-
toms related to the disease, birth weight, and gestational age.
The study was approved by the Healthcare Ethics Committee
of Santiago de Compostela University Hospital. Two indepen-
dent measurements were performed in samples which present
lower activity than the cutoff. Informed consent was asked to
patients with confirmed low levels of enzymatic activity be-
fore performing GLA sequencing. A genetic study was also
performed to the patient’s parents of this group upon consent.
Measurements Enzymatic activity of α-galactosidase A (α-
GalA) was measured following the fluorometric method de-
scribed by Chamoles [11]. Briefly, the assay was performed
on triplicates in buffer citrate-phosphate 0.15 M pH 4.2, using
4-methylumbeliferil-galactopiranoside substrate (2 mM,
Glycosinth, UK) in the presence of N-acetylgalactosamine
(70 mM, Sigma-Aldrich). α-GalA activity was expressed as
micromoles of substrate per hour and liter of blood (μmol/Lh).
For genetic study, the seven exons of GLAwere amplified
by PCR with specific primers and were sequenced by the
Sanger method, using the Chromas 2.4. software to detect
point mutations and small deletions or insertions in exons
and near intronic regions (±25 bp).
Data analysis Correlation of enzymatic activity with birth
weight and gestational age was analyzed using the Pearson
correlation coefficients. The association between enzymatic
activity and gestational age (<35 vs. >35 weeks) or low birth
weight (<2500 g) was tested using χ2 test for contingency
tables. The cutoff value for enzymatic activity was determined
using the 0.5 percentile and was adjusted to take into account
correlating variables like sex, weight, and gestational age. To
establish the appropriate cutoff value, we quantify the α-GalA
activity in a total of 2168 healthy newborns. The average
activity was 5.1 μmol/Lh (CI 95% 5.0–5.2) and the median
was 4.57 (95% CI 4.46 to 4.71). Prevalence, positive predic-
tive value (PPV), and method accuracy for the diagnostic pro-
tocol were calculated using the MedCalc 16.4.3 software
(Oostende University, Belgium); CI was indicated.
Results
To identify FD positive subjects, we determined a cutoff value
of 1.7 μmol/Lh applying the 0.5 percentile to the cohort of
enzymatic activity data; however, this reference was raised at
2 μmol/Lh so that we could take into account correlating
variables and avoid false negatives.
Indeed, heterozygous girls have higher residual activity
compared to boys, and we calculated thatα-GalA activity also
correlates with birth weight (r = −0.2468, p < 0.0001, 95%
CI = −0.3027 to −0.1892, F-ratio = 68.1874, p < 0.001) and
gestational age (r = −0.3026 p < 0.0001, 95% CI = −0.3581 to
−0.2450, F-ratio = 99.9011, p < 0.001). Pre-term babies
(<35 weeks gestation) and low birth weight newborns
(<2500 g) present higher enzyme levels than term infants
(9.1 versus 4.9, t = 10.721, DF = 991, p < 0.0001) and normal
weight children (7.0 versus 4.9, t = 8.499, DF = 1051,
p < 0.0001).
Following flourimetric tests, 14,494 samples presented α-
GalA activity ≥2 μmol/Lh, while enzymatic levels in 106
samples were lower than the cutoff (Fig. 1), as confirmed by
a second measurement. Among patients with enzymatic activ-
ity below ≥2 μmol/Lh, we obtained consent forGLA sequenc-
ing in 101 subjects (68 males and 33 females), while the re-
maining 5 (females) were excluded from the analysis.
Genetic variants in GLA were detected in 37 patients (20
males and 17 females) as summarized in Table 1.
The p.M290I (c.870G>A) identified in one male patient
was previously described as pathogenic and associated to clas-
sical FD. Methionine 290 is conserved in at least three α-
galactosidase and one β-galactosidase orthologues, and its
substitution is related to the misfolding of the protein [12].
The p.F18Y (c.53T>A) missense non-characterized variant
was identified in a heterozygous patient, who at the moment
does not have a definitive diagnosis of FD. This single nucle-
otide polymorphism (SNP) was not reported earlier in the
Human Mutation Database; [13] however, the database in-
cludes as pathogenic a FD-related mutation of phenylalanine
18 with serine. Like serine, tyrosine is more polar than phe-
nylalanine and may alter the hydrophobic interactions of the
molecule. A clinical follow-up of the girl, who inherited the
mutation from the mother, revealed that she presented derma-
tological lesions of unidentified cause. She also suffered tran-
sitory respiratory impairment and underwent transfontanellar
ultrasound, since she presented macrocephalic features, al-
though the exam failed to detect any kind of alteration. At
the age of 4, she was also explored in cardiology because
extrasystoles were detected. The mother of the index case
refused to further collaborate to the study; however, she pre-
sented several skin lesions, which have not been studied and
the grandfather of the index case died at the age of 32 due to
melanoma. Other members of the family (siblings of the
mother of the index case, 3 females and 2 males) presented
several non-specific symptoms but refused to be tested for FD.
One uncle presented angiokeratoma-like lesions and a lesion
on the knee which was biopsied. Biopsy examination deter-
mined the presence of inflammation and enlarged cells
with birefringent-deposited material. One aunt presented
recurrent abdominal pain, hearing loss, and occasional pru-
ritus in the extremities.
In the remaining subjects, we detected genetic variants of
uncertain significance (GVUS) such as p.R118C (c.352C>T),
p.A143T (c.427G>A), and p.S126G (c.376A>G), as well as
the pseudodeficiency allele p.D313Y (c.937G>T), and the
intronic variants rs2071225 and rs2071397.
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Since enzymatic testing is not conclusive for females, we
calculated the prevalence of FD and the performance of the
diagnostic test considering the data obtained in the male pop-
ulation. The estimated prevalence is of 0.013% (1:7575
males); the PPV of the current screening is 1.47% with a
method accuracy of 99.12% (CI 98.9–99.3) and a false posi-
tive rate of 0.88%.
Discussion
The FD prevalence estimated in this study is considerably more
frequent than the initially described [14], and the values are
comparable to those reported in other studies, which were car-
ried out in different geographical areas. A study conducted in
Japanese newborns [15] reported a prevalence of 1:7057 live
births with FD classical phenotype, increased to 1:3024, includ-
ing uncharacterized GLA variants. Previous NBS studies in
Taiwan and Italy estimated a prevalence of, respectively,
1:2445 live births and 1:3100 males [16, 17], including GLA
variants of uncertain clinical significance. Van der Tol et al. [18]
conducted a systematic review of FD screening studies to re-
calculate the prevalence of the pathology by discriminating
mutations and GVUS and concluded that 90% of the identified
cases harbored variants of unclear significance. In European
asymptomatic newborns, the most frequent genetic alterations
reported p.A143T, p.R112H, and p.D313Y, while in a
Taiwanese study, rs2071397 was found in 83% of the patients.
Controversial variants were also detected in 84 out of 28,165
patients enrolled in screening studies of high-risk populations
(prevalence = 0.3%), in which the classical FD phenotype has a
prevalence of 0.12%. Since in screening studies, where GVUS
were identified, the selected patients presented cardiac lesion or
end-stage renal disease, it is still arguable if these genotypes,
which are relatively frequent in the general population
(p.A143T = 0.09% and p.R118C = 0.04%), could be directly
related to FD and up to date it is recommended not to consider
these subjects as patients unless a biopsy examination confirms
the presence of deposits [19].
The detection of p.D313Y SNP, which is present in 0.3% of
the population [18], is also frequent in previous screening
studies; however, there is a general consent in considering this
SNP as a pseudodeficiency allele [20].
The nucleotide substitutions in intronic region identified in
our study, as well as in previous reports, are validated SNPs
[21]. Even if it has been shown that when these SNPs are part
of complex haplotypes, they can be involved in GLA tran-
scription defects [22, 23], the mechanisms through which
transcription is inhibited have not been clarified and these
individuals cannot be considered as patients without fur-
ther evidences.
The most recent NBS studies performed in Washington
[24] and Missouri [9] report a FD prevalence of 1:7800 live
births (not specifying how many late onset or GVUS) or
1:2913 (10 classic, 4 late onset, and 1 GVUS), respectively.
The identified subjects in the Missouri study with GLA vari-
ants are extensively followed up to determine which individ-
uals actually develop a FD-related phenotype. This follow-up
is essential to identify pathogenic and late-onset variants in
order to establish a definitive diagnosis.
The second aim of our study was to evaluate the suitability
of performing NBS screening for FD in our community by
implementing an appropriate method. Although the applied
protocol allowed to reach results which are consistent with
α-Gal A 
acvity in DBS

























Fig. 1 A description of the FD
screening protocol. Percentage of
subjects (males and females)
identified in each step are
indicated
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the ones reported in other literature, the method could be me-
liorated to reduce false-positive rates (FP = 0.88%) and there-
fore cost of determinations. Nevertheless, the estimated
method accuracy and PPV are comparable with the ones
obtained, using the same samples for the determination of
immunoreactive trypsinogen (PPV = 4%, method accura-
cy = 99.2%) and thyroid stimulating hormone (PPV = 18%
and method accuracy = 99.8%) by immunofluorometric
assays. These tests are routinely carried out in our hospitals
for the first step detection of cystic fibrosis (CF) and con-
genital hypothyroidism using DBS. However, the protocol
we apply for CF and congenital hypothyroidism screening
requires a second step analysis for those samples that pres-
ent indeterminate values (close to cutoff points). For CF
detection, samples are directed to DNA analysis by
mass spectrometry (Maldi-Tof), using a chip with 277
Table 1 α-GalA activity levels
obtained in two independent
biochemical analyses and
mutations detected by genetic
sequencing. Female heterozygous
patients are indicated in italics.
The classical FD patient was
highlighted with bold font





1 M 0.6 0.6 M290I, rs2071397,
rs2071225
2 F 1.6 1.6 F18Y/wt
3 F 2.0 1.5 S126G, rs2071397/wt
4 M 1.7 1.4 A143T
5 F 1.7 1.9 A143T/wt
6 M 0.7 1.1 A143T
7 M 1.7 1.3 R118C
8 F 1.4 1.6 R118C/wt
9 M 1.1 1.5 R118C
10 M 1.4 1.0 R118C
11 M 1.7 1.6 R118C
12 M 2.0 1.8 R118C
13 F 1.9 1.5 D313Y, rs2071225,
rs2071397/wt
14 M 1.9 1.2 D313Y
15 M 1.8 1.9 D313Y
16 M 1.7 1.6 D313Y
17 F 1.9 1.7 rs2071225/wt
18 F 1.9 1.8 rs2071225/wt
19 M 0.6 0.3 rs2071225
20 M 1.4 1.8 rs2071397
21 F 1.8 1.6 rs2071397/wt
22 F 1.5 2.0 rs2071397/wt
23 M 1.3 1.1 rs2071397
24 F 1.4 1.9 rs2071397/wt
25 F 1.8 1.8 rs2071397/wt
26 M 1.3 1.9 rs2071397
27 F 1.6 1.8 rs2071397/wt
28 M 1.2 1.8 rs2071225, rs2071397
29 F 1.7 2.0 rs2071225, rs2071397/wt
30 M 1.4 1.5 rs2071225, rs2071397
31 F 1.8 0.9 rs2071225, rs2071397/wt
32 M 1.6 1.8 rs2071225, rs2071397
33 F 1.9 1.7 rs2071225, rs2071397/wt
34 M 1.8 1.6 rs2071225, rs2071397
35 M 1.9 1.9 rs2071225, rs2071397
36 F 2.0 1.9 rs2071225, rs2071397/wt
37 F 1.9 1.7 rs2071225, rs2071397/wt
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mutations. In the same fashion, a second step analysis
based on the quantification by mass spectrometry of the
enzymatic reaction products [25] could help to reduce
false-positive rates in the screening for FD.
Lowering the cutoff level that we established for α-GalA
may also help to reduce false-positive rates of the enzymatic
screening, in case that the test is performed in male samples
only. The cutoff value of enzymatic activity could have been
overestimated in male samples, since it was determined in
2168 healthy newborns of both sexes.
On the other hand, performing enzymatic test in newborn
females may help to the early identification of at least a per-
centage of the affected females. In our study, we detected a
heterozygous subject with a new non-characterized variant of
GLA (p.F18Y), as well as two newborn girls with GVUS. In
the case that further studies confirm a pathogenic state of
p.F18Y, the prevalence of FD in the whole population will
be of 0.014% (1:7297; PPV of 2%, a method accuracy of
99.3%, a false-positive rate of 0.67%, and a 95% CI of 75–
100), which are values similar to the ones obtained in male
population. This suggests that the percentage of false nega-
tives in our female population is not extremely high.
Nonetheless, genetic sequencing is the only method that cur-
rently is efficient for a reliable detection of female patients and
we have to be well aware that an activity above the cutoff does
not exclude FD in females.
When considering newborn screening for FD, there are
important issues to take into account. Given the refusal of
ACHDNC to include FD in the RUSP, experts maintain an
open position regarding NBS for FD or Gaucher disease,
which meets favorable criteria in terms of frequency of the
diseases and available diagnostic methods and therapies
[26]. Even if the ambiguity regarding the prognosis of the
subject with GVUS is an undesirable outcome in screening,
the possibility to establish an early therapeutic protocol counts
as a major pro in favor of neonatal FD screening, since the
available treatments are more efficient when the therapy is
started in the early symptomatic phase. We believe that the
benefits of early diagnosis, especially in the case of posi-
tive subjects, cannot be underestimated; therefore, we sug-
gest reconsidering the position adopted on FD screening by
ACHDNC, based on the growing amount of data
appointing to high frequency of GLA mutations in the pop-
ulation and the perspective of new therapeutic strategies.
This paper largely discusses the characteristics of genetic
modifications in order to discriminate between pathogenic
mutations and GVUS and can help to develop adequate
follow-up programs. Indeed, in order to support a change
in the current policy, a follow-up of the subjects identified
in pilot studies will be determinant and should be associ-
ated to a deeper functional characterization of the contro-
versial variants, which includes transcription analysis and
epigenetic data.
Conclusions
The estimated prevalence for FD classical phenotype in male
newborns of Galicia is of 0.013%. These values, as well as the
feasibility and efficacy of the proposed method (method ac-
curacy = 99.12%, PPV = 1.47%), postulate FD as a candidate
for systematic screening. However, further characterization of
the frequently identified variants of GLAwith uncertain clin-
ical significance is necessary to establish appropriate protocols
for patients’ management.
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